Muhammad Haris Khan

Muhammad Haris Khan

Auto-generated profile, based on publicly available information

Muhammad Haris Khan

Department of Medicine Saidu Medical College Swat Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2025 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
UKUbaid Khan
Ubaid Khan
ZMZuhair Majeed
Zuhair Majeed
MKMuhammad Haris Khan
Muhammad Haris Khan
AEAhmed Bostamy Elsnhory
Ahmed Bostamy Elsnhory
AAAhmed Mazen Amin
Ahmed Mazen Amin
MAMohamed Abuelazm
Mohamed Abuelazm
Background: Type 2 diabetes mellitus (T2DM) accounts for over 90% of diabetes cases worldwide. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity by activating PPAR‐γ. Evidence on its efficacy and safety as an add‐on to metformin and SGLT2 inhibitors in inadequately controlled T2DM is limited. This systematic review and meta‐analysis evaluates pioglitazone's role as a third‐line therapy for improving glycaemic control in addition to metformin and Dapagliflozin.Methodology: We conducted comprehensive searches across PubMed, CENTRAL, WOS, Scopus and EMBASE until December 2024. Pooled data were reported using risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, along with a 95% confidence interval (CI). This systematic review and meta‐analysis is registered with PROSPERO ID: CRD42024612005.Results: We included three RCTs with 885 patients. Pioglitazone add‐on therapy significantly reduced HbA1c levels (MD: −0.41; 95% CI: −0.54 to −0.27, p = < 0.00001, I2 = 0%), fasting blood glucose (MD: −11.91; 95% CI: −16.34 to −7.48, p = < 0.00001, I2 = 0%), Homeostatic Model Assessment for Insulin Resistance (HOMA‐IR) (MD: −0.65; 95% CI: −1.05 to −0.25, p = 0.001, I2 = 4.89%), increased the rate of achieving HbA1c < 7% (RR: 2.09; 95% CI: 1.66 to 2.64, p = < 0.00001, I2 = 0%), and HbA1c < 6.5% (RR: 2.19; 95% CI: 1.36 to 3.53, p = 0.001, I2 = 0%). However, there was no difference regarding Homeostasis model assessment of β‐cell function (HOMA‐β) between the two groups (MD: 2.73; 95% CI: −5.24 to 10.70, p = 0.5, I2 = 27.53%).Conclusion: Pioglitazone add‐on therapy significantly improved glycaemic control by reducing HbA1c, fasting blood glucose and HOMA‐IR while increasing the likelihood of achieving HbA1c targets. However, no significant difference was observed in HOMA‐β between groups. These findings suggest the potential benefit of pioglitazone in enhancing glycaemic outcomes in diabetes management.

7 March 2025 in Indian Pacing and Electrophysiology Journal
Verified
Journal Article
Open access
UKUbaid Khan
Ubaid Khan
FKFirst42 Khlidj
First42 Khlidj
AIAhmed A. Ibrahim
Ahmed A. Ibrahim
AAAhmed Mazen Amin
Ahmed Mazen Amin
MRMohamed Saad Rakab
Mohamed Saad Rakab
KCKashif Chaudhry
Kashif Chaudhry
Ventricular tachycardia (VT) is a common chronic complication of ischemic heart disease (IHD), even in the era of contemporary coronary intervention. The use of implantable cardioverter-defibrillators (ICDs) has reduced mortality, but ICD shocks can be painful and traumatizing. Catheter ablation has been posited to reduce VT incidence and is commonly used in IHD patients when antiarrhythmic drugs do not suppress VT. We aim to review the clinical efficacy and safety of catheter ablation vs medical therapy in patients with IHD. We conducted comprehensive searches across PubMed, CENTRAL, WOS, Scopus, and EMBASE until Feb 2024. Pooled data were reported using risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes. This systematic review and meta-analysis was registered with PROSPERO ID: CRD42024551760. We included Eight RCTs with a total of 1,252 patients. Patients who underwent ablation had a lower risk of VT storm compared to those who received medical therapy [RR: 0.74 with 95% CI: (0.60, 0.91), P =0.005), Compared to medical treatment, the catheter ablation group also required less appropriate ICD therapy [RR: 0.72 with 95% CI (0.57, 0.90), P < 0.01), and fewer appropriate ICD shocks [RR: 0.75 with 95% CI (0.57, 0.0.99), P = 0.04). However, there was no significant difference in VT/VF recurrence [RR: 0.94 with 95% CI (0.83, 1.04), P = 0.33) and all-cause mortality [RR: 0.87 with 95% CI (0.70, 1.09), P = 0.22). Catheter ablation is associated with a reduction in ventricular storms, ICD therapy, and ICD shocks while demonstrating similar safety in managing VT in IHD patients compared to medical therapy alone.

27 January 2025 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
MOMuhammad Osama
Muhammad Osama
MKMuhammad Haris Khan
Muhammad Haris Khan
SKSafeena Khan
Safeena Khan
AHAmna Hussain
Amna Hussain
ATAmmara Tahir
Ammara Tahir
WRWajeeh Ur Rehman
Wajeeh Ur Rehman
Background: Anti-CD38 monoclonal antibodies (mAbs) have significantly changed the multiple myeloma treatment landscape. This meta-analysis compared the efficacy and safety of anti-CD38 mAb-based therapy versus standard therapy in newly diagnosed multiple myeloma (NDMM) patients. Methods: We performed a comprehensive literature search on PubMed, the Cochrane Database, and ClinicalTrials.gov. The primary outcomes were progression-free survival (PFS) and minimal residual disease (MRD) status. Dichotomous outcomes were pooled using risk ratio (RR) along with the 95% confidence interval (CI) in RevMan 5.4. Subgroup analysis and meta-regression analysis were performed. The RoB 2.0 tool was used to assess the risk of bias. Results: Our meta-analysis included 11 randomized controlled trials. There were 5270 patients; 3040 TEs and 2230 TIEs. Anti-CD38 mAbs significantly improved MRD negativity (RR 1.94, 95% CI: 1.59–2.37; p < 0.00001) and PFS (RR 0.51, 95% CI: 0.45–0.58; p < 0.00001). Subgroup analyses revealed better outcomes for both the TE (MRD: RR 1.52, 95% CI: 1.37–1.68; PFS: RR 0.43, 95% CI: 0.34–0.54) and TIE (MRD: RR 3.49, 95% CI: 2.65–4.61; PFS: RR 0.55, 95% CI: 0.47–0.64) populations. Meta-regression revealed that Eastern Cooperative Oncology Group (ECOG) score 0 significantly influenced MRD status (β = −0.015, p < 0.05), whereas ECOG scores 1 and 2 lacked statistical significance. Subgroup analysis revealed that PFS was significantly different between standard (RR 0.47) and high (RR 0.81) cytogenetic risk groups. Conclusion: In NDMM patients, anti-CD38 mAb-based therapy significantly improved MRD status, and PFS compared with standard therapy alone, in both TE and TIE patients, suggesting a favorable benefit–risk profile.

2 May 2025 in World Neurosurgery
Verified
Journal Article
Open access
MAMohammad Ashraf
Mohammad Ashraf
SASophia Ahmed
Sophia Ahmed
MNMuhammad Asfandyar Nadir
Muhammad Asfandyar Nadir
ZTZuha Tariq
Zuha Tariq
MIMahrukh Iqbal
Mahrukh Iqbal
CGConor S. Gillespie
Conor S. Gillespie
Real-time intraoperative imaging with neuronavigation is a valuable adjunct in the surgical management of intra-axial brain tumours. While intraoperative magnetic resonance imaging (iMRI) is the gold standard, recent advances in technology have explored the utility of intraoperative computed tomography (iCT) as an alternative. A systematic review was conducted by searching multiple databases, including MEDLINE, PubMed, Scopus, Cochrane Library, and Web of Science, for studies published from 1982 to 2024. Studies that evaluated the use of iCT in intra-axial brain tumour surgeries and reported on outcomes such as the extent of tumour resection (EOTR), residual tumour detection, and postoperative complications were included. Thirteen studies met the inclusion criteria. Overall, recent improvements in iCT's soft tissue imaging quality have increased its utility in intra-axial brain tumour surgeries. iCT was found to improve tumour resection accuracy in some instances, helping neurosurgeons detect residual tumours and refine surgical strategies. However, conclusions about its impact on long-term outcomes are limited by the lack of data on molecular tumour characteristics and adjuvant therapies. Further high-quality prospective work is needed to validate the role of iCT in improving key outcome parameters in neuro-oncology. Until then, iCT remains an adjunct whose use can be considered in select cases. Continued research on iCT is warranted to determine further indications in intra-axial brain tumour surgery.

1 July 2025 in Journal of Arrhythmia
Verified
Journal Article
Open access
UKUbaid Khan
Ubaid Khan
AAAhmed Mazen Amin
Ahmed Mazen Amin
ZMZuhair Majeed
Zuhair Majeed
MKMuhammad Haris Khan
Muhammad Haris Khan
MAMahmoud Shaaban Abdelgalil
Mahmoud Shaaban Abdelgalil
ANAnum Nawaz
Anum Nawaz
Background: Intracardiac echocardiography (ICE) is an innovative technique that has emerged as an alternative to transesophageal echocardiography (TEE) to guide the implantation of a left atrial appendage occlusion (LAAO) device in patients with nonvalvular atrial fibrillation (AF) who cannot tolerate anticoagulants. Purpose: We aim to review the clinical efficacy and safety of ICE compared to TEE to guide the implantation of LAAO devices in patients with AF. Methods: We conducted comprehensive searches across PubMed, CENTRAL, Web of Science, Scopus, and EMBASE until March 2024. Pooled data were reported using risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, along with a 95% confidence interval (CI). This systematic review and meta‐analysis was registered with PROSPERO ID: CRD42024542537 . Results: We included 19 studies involving 44,706 patients. ICE was associated with a statistically significant high procedure success rate compared to TEE (RR: 1.0055 with 95% CI [1.0006, 1.0104], p = 0.01), but there was no difference in procedure duration (MD: 3.07 with 95% CI [−4.67, 10.80], p = 0.44) between the two groups. However, compared to the ICE group, patients undergoing LAAO under TEE guidance required more than one device more often (RR: 1.39 with 95% CI [1.23, 1.57], p < 0.01). The TEE group also reported a reduced incidence of pericardial effusion compared to the ICE group (RR: 0.65 with 95% CI [0.50, 0.85], p < 0.01). Conclusion: Our meta‐analysis concluded that ICE can be a viable alternative to TEE for guiding LAAO, particularly in patients unsuitable for general anesthesia. It can also reduce the need for GA and adverse effects and resources associated with it, require fewer devices, and demonstrate comparable safety and efficacy outcomes, though it may increase the risk of pericardial effusion. Further prospective trials are warranted.

1 February 2026 in Future Cardiology
Verified
Journal Article
Closed access
UKUbaid Khan
Ubaid Khan
MAMahmoud Shaaban Abdelgalil
Mahmoud Shaaban Abdelgalil
MKMuhammad Haris Khan
Muhammad Haris Khan
JAJunaid Ali
Junaid Ali
ZMZuhair Majeed
Zuhair Majeed
MAMuhammad Aamir
Muhammad Aamir
Many patients remain functionally limited after transcatheter aortic valve replacement (TAVR) despite successful correction of aortic stenosis. Exercise-based cardiac rehabilitation (EBCR) is effective in other cardiac populations, but its benefits after TAVR remain uncertain. This study evaluated the impact of EBCR on functional capacity, cardiac function, quality of life, and safety outcomes in post-TAVR patients. A systematic review and meta-analysis of randomized controlled trials (RCTs) published through February 2025 was conducted using major databases. Outcomes were pooled using mean differences or risk ratios with 95% confidence intervals. Six RCTs with 272 patients were included. No significant difference was found between EBCR and usual care for peak VO2 change (MD: 1.46, 95% CI: [-0.16 to 3.08], p = 0.076) and six-minute walk distance (6MWD) change (MD: 18.72, 95% CI: [-2.24 to 39.68], p = 0.08). Similarly, no significant difference was observed between EBCR and usual care for left ventricular ejection fraction (LVEF) change (MD: 1.31, 95% CI: [-2.06 to 4.69], p = 0.45), and aortic valve orifice area change (AVOA) (MD: -0.03, 95% CI: [-0.24 to 0.18], p = 0.78). EBCR did not significantly improve outcomes after TAVR; however, near-significant trends in functional capacity warrant further large-scale investigation. PROSPERO ID CRD420250652719.